Abstract
The objective of this study was to develop a nanodelivery system containing a mucoadhesive polymer hyaluronic acid (HA) for oral delivery. Metformin was used as a model drug. Blank and drug-loaded HA nanostructures were prepared by precipitation method and characterized for particle size (PS), zeta potential (ZP), physical stability (over 65 days), surface morphology, moisture content, and physical state of the drug in the nanostructures. The cytotoxicity and hemolysis potential of the delivery system was assessed in Caco-2 cells and whole human blood, respectively. The in vitro release of metformin and its uptake in Caco-2 cells was evaluated using high-performance liquid chromatography. Ex vivo permeability of metformin was measured through goat intestinal membrane. The nanoparticles were physically stable and neutrally charged with an average PS of 114.53 ± 12.01 nm. This nanodelivery system existed as nanofibers containing metformin in a crystalline state. This delivery system released the drug rapidly with > 50% of metformin released within 1 h. Cellular uptake studies on Caco-2 cells indicated higher uptake of metformin from nanoparticle as compared to metformin in solution, up to first 45 min. Ex vivo permeability studies on the other hand showed a higher metformin permeability from solution relative to that from nanoparticles through the goat intestinal membrane. Metformin nanoparticles were non-toxic at therapeutic concentrations in Caco-2 cells and showed no hemolytic effect to RBCs. This study indicates the preparation, characterization, as well as the potential use of HA nanostructures for oral delivery.
Similar content being viewed by others
References
Roglic G. WHO Global report on diabetes: A summary. International Journal of Noncommunicable Diseases. 2016;1(1):3.
Centers for Disease Control and Prevention. National diabetes statistics report, 2014: estimates of diabetes and its burden in the United States. Atlanta, GA: US Department of Health and Human Services. 2014.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2004;27(suppl 1):s5–10.
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3–19.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358(19):2003–15.
Tripathi KD. Essentials of medical pharmacology. JP Medical Ltd; 2008;266–270.
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–31.
Klip A, L A L. Cellular mechanism of action of metformin. Diabetes Care. 1990;13(6):696–704.
Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 2008;36(8):1650–8.
Gonga L, Goswami S, Giacominic KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;22(11):820–7.
Lee WL, Wee P, Nugraha C, Loo SCJ. Gastric-floating microcapsules provide controlled and sustained release of multiple cardiovascular drugs. J Mater Chem B. 2013;1(8):1090–5.
Cheng C-L, Yu LX, Lee H-L, Yang C-Y, Lue C-S, Chou C-H. Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci. 2004;22(4):297–304.
Carino GP, Mathiowitz E. Oral insulin delivery 1. Adv Drug Deliv Rev. 1999;35:249–57.
Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, MNVR K. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007;119(2):197–206.
Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations—opportunities and limitations. Drug Discov Today Technol. 2012;9(2):e71–174.
Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm. 2011;412(1–2):123–31.
Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res. 2007;24(12):2198–206.
Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 2007;119(1):77–85.
Meena AK, Ratnam VD, Chandraiah G, Ankola DD, Rao RP, Kumar MR. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure® in treating hyperlipidemia. Lipids. 2008;43(3):231–41.
Agrahari V, Zhang C, Zhang T, Li W, Gounev TK, Oyler NA, et al. Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro. AAPS J. 2014;16:181–93.
Sanka ASK, Sythana S, Jhansi A, Shanmugasundharam P. Development and validation for simultaneous estimation of sitagliptin and metformin in pharmaceutical dosage form using RP-HPLC method. Int J Pharmtech Res. 2013;5(4):1736–44.
Debebe Z, Nekhai S, Ashenafi M, Lovejoy DB, Kalinowski DS, Gordeuk VR, et al. Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. J Chromatogr B Anal Technol Biomed Life Sci. 2012;906:25–32.
Sandri G, Rossi S, Ferrari F, Bonferoni MC, Zerrouk N, Caramella C. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol. 2004;56(9):1083–90.
Saettone MF, Giannaccini R, Chetoni P, Torracca MT, Monti D. Evaluation of high- and low-molecular weight fractions of sodium hyaluranate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. Int J Pharm. 1991;72:131–9.
Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan ): a review. Vet Med (Praha). 2008;2008(8):397–411.
Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14:1568–73.
Verma S, Kumar S, Gokhale R, Burgess D. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2011;406(1):145–52.
Sonaje K, Lin Y-H, Juang J-H, Wey S-P, Chen C-T, Sung H-W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 2009;30(12):2329–39.
Karlsson J, Ungell A-L, Gråsjö J, Artursson P. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur J Pharm Sci. 1999;9(1):47–56.
Manconi M, Nácher A, Merino V, Merino-Sanjuan M, Manca ML, Mura C, et al. Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation. AAPS PharmSciTech. 2013;14:485–96.
ACKNOWLEDGEMENTS
The authors would like to thank Dr. Alexey Krasnoslobodtsev (UNMC) for the AFM analysis and Dr. Raj Suryanarayanan (University of Minnesota) for the XRD analysis.
Funding
Financial support from the School of Pharmacy and Health Professions is greatly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhujbal, S., Dash, A.K. Metformin-Loaded Hyaluronic Acid Nanostructure for Oral Delivery. AAPS PharmSciTech 19, 2543–2553 (2018). https://doi.org/10.1208/s12249-018-1085-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-018-1085-1